Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q1 EPS by 44c

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($1.24), $0.44 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $3.55 million versus the consensus estimate of $37.66 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Investing.com’s stocks of the week
• Hafnia Limited (HAFN) Tops Q2 EPS by 1c